Activus Pharma, a wholly owned subsidiary of Sosei Group, has entered into a technical alliance agreement with CEOLIA Pharma.
Subscribe to our email newsletter
As per the agreement, CEOLIA and Activus will jointly conduct research and development to assess the feasibility of development of a novel oral formulation using Activus Pure Nano-particle Technology (APNT).
Sosei is a biopharmaceutical company anchored in Japan. It practises a reduced risk business model by acquiring a global reach, the company said.
CEOLIA is a specialty pharmaceutical company that focuses on development and commercialization of pharmaceutical products for the sensory organs ear, nose and throat.